ROYAL OAK, Mich. — IMMUNIS.AI, an immunogenomics company developing blood-based cancer surveillance technologies, today announced that results from a prostate cancer risk stratification study evaluating the company’s novel blood-based liquid biopsy platform were published in The Journal of Urology. The results validate the ability of the platform to accurately stratify...
Latest News
JERUSALEM, Israel — Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, today announced positive top line results from the Phase 2a trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients. The study demonstrated statistically significant efficacy as measured by change in the slope decline of ALSFRS-R. The drug was well tolerated, and the...
CULVER CITY, Calif. – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has administered its proprietary Natural Killer cells to more than 100 patients. The cells were administered as part of combination therapies in trials across multiple indications, including pancreatic, triple-negative breast, and Merkel Cell Carcinoma cancers....
CULVER CITY, Calif. – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the launch of the preclinical development of its liquid tumor pipeline with the publication of results from its Phase 1 study evaluating Anktiva™ (N-803), its IL-15 superagonist, in combination with Rituxan® (rituximab), an anti-CD20 monoclonal antibody...
CULVER CITY, Calif. — ImmunityBio, Inc. a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety portions of a clinical trial that is studying ImmunityBio’s investigational cancer vaccine of a tri-valent combination of antigens delivered by a second-generation Adenovirus vector (Tri-Ad5 CEA/MUC1/brachyury) together...
CULVER CITY, Calif. — ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its investigational immune-boosting regimen including ANKTIVA® (nogapendekin alfa inbakicept-pmln) in this pilot study (NCT06061809). All five patients achieved 100% disease control with the regimen that combines...
CULVER CITY, Calif. — ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) demonstrates efficacy at 12 and 36 months, including disease-free survival (DFS), disease-specific survival (DSS), long-term progression-free survival (PFS), and high cystectomy avoidance in patients with BCG-unresponsive high-grade...
While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value 0.005, HR: 0.46 [0.26, 0.80]) observed in 3rd-6th line metastatic pancreatic cancer, correlated with reversal of lymphopenia. Patients with lower tumor burden and...
CULVER CITY, Calif. — ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today early findings from its QUILT-106 Phase I trial, showing highly promising complete responses in the first two patients treated to date with late-stage Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural...
OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious...